Unacylated Ghrelin Regulates Glucose-Sensitive Neurons Activity and Glycolipid Metabolism via Orexin-A Neurons in the Lateral Hypothalamic Area

Abstract

The objective of the study was to investigate the regulatory actions of unacylated ghrelin (UAG) on glucose-sensitive (GS) neurons and glycolipid metabolism in the lateral hypothalamus area (LHA) and its involvement with orexin-A-immunopositive neurons. The effects of UAG administered into the LHA on GS neurons discharges and glycolipid metabolism were detected by single neuron discharge recording, biochemical index analysis and quantitative real-time PCR; the level of c-fos protein in orexin-A-immunopositive neurons was observed using immunofluorescence staining. UAG microinjected into the LHA activated glucose-inhibited neurons, which were partially blocked by pre-administration of anti-orexin-A antibody in the LHA. Furthermore, UAG microinjected into the LHA significantly reduced serum triglycerides (TG), total cholesterol, low-density lipoprotein cholesterol, blood glucose, insulin and hepatic TG levels, while elevated serum high-density lipoprotein cholesterol levels. UAG elevated the mRNA expression of carnitine palmitoyltransferase-1 and reduced the mRNA expression of acetyl-CoA carboxylase-1 in the liver. The above-mentioned effects of UAG were partially blocked by pre-administration of anti-orexin-A antibody. The expressions of orexin-A and c-fos were observed in the LHA. After UAG injection into the LHA, some neurons showed double labeling, and the percentage of double-labeled orexin-A/c-fos neurons in orexin-A-immunopositive neurons increased significantly. UAG in the LHA regulates glycolipid metabolism by activating orexin-A-immunopositive neurons in the LHA.

Key words

unacylated ghrelin - lateral hypothalamus area - glycolipid metabolism - glucose-sensitive neurons - orexin-A-immunopositive neurons

Publication History

Received: 20 December 2019

Accepted after revision: 17 June 2020

Article published online:
27 July 2020

• References

• 1 Collden G, Tschop MH, Muller TD. Therapeutic potential of targeting the ghrelin pathway. Int J Mol Sci 2017; 18: E798
• 2 van der Lely AJ, Tschop M, Heiman ML. et al. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25: 426-457
• 3 Hosoda H, Kojima M, Matsuo H. et al. Ghrelin and des-acyl ghrelin: Two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 2000; 279: 909-913
• 4 Muller TD, Nogueiras R, Andermann ML. et al. Ghrelin. Mol Metab 2015; 4: 437-460
• 5 Heppner KM, Tong J, Kirchner H. et al. The ghrelin O-acyltransferase-ghrelin system: a novel regulator of glucose metabolism. Curr Opin Endocrinol Diabetes Obes 2011; 18: 50-55
• 6 Nakazato M, Murakami N, Date Y. et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198
• 7 Zhang W, Chen M, Chen X. et al. Inhibition of pancreatic protein secretion by ghrelin in the rat. J Physiol 2001; 537: 231-236
• 8 Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-913
• 9 Broglio F, Gottero C, Prodam F. et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab 2004; 89: 3062-3065
• 10 Delhanty PJ, Neggers SJ, van der Lely AJ. Des-acyl ghrelin: A metabolically active peptide. Endocr Devel 2013; 25: 112-121
• 11 Fittipaldi AS, Hernández J, Castrogiovanni D. et al. Plasma levels of ghrelin, des-acyl ghrelin and LEAP2 in children with obesity: Correlation with age and insulin resistance. Eur J Endocrinol 2020; 182: 165-175
• 12 Wu TH, Chiu CC, Goh KK. et al. Relationship between metabolic syndrome and acylated/desacylated ghrelin ratio in patients with schizophrenia under olanzapine medication. J Psychopharmacol 2020; 34: 86-92
• 13 Jin T, Jiang Z, Luan X. et al. Exogenous Orexin-A microinjected into central nucleus of the amygdala modulates feeding and gastric motility in rats. Front Neurosci 2020; 14: 274
• 14 Boss C. Orexin receptor antagonists–a patent review (2010 to August 2014). Exp Opin Therap Patents 2014; 24: 1367-1381
• 15 Blais A, Drouin G, Chaumontet C. et al. Impact of Orexin-A treatment on food intake, energy metabolism and body weight in mice. PLoS One 2017; 12: e0169908
• 16 Boss C, Roch C. Orexin research: patent news from 2016. Exp Opin Therap Patents 2017; 27: 1123-1133
• 17 Marcus JN, Aschkenasi CJ, Lee CE. et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Compar Neurol 2001; 435: 6-25
• 18 Laburthe M, Voisin T. The orexin receptor OX(1)R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs. Br J Pharmacol 2012; 165: 1678-1687
• 19 Yamada H, Okumura T, Motomura W. et al. Inhibition of food intake by central injection of anti-orexin antibody in fasted rats. Biochem Biophys Res Commun 2000; 267: 527-531
• 20 Blais A, Drouin Gaëtan, Chaumontet C. et al. Impact of Orexin-A treatment on food intake, energy metabolism and body weight in mice. PLos One 2017; 12: e0169908
• 21 Pruszynska-Oszmalek E, Kolodziejski P, Kaczmarek P. et al. Orexin A but not orexin B regulates lipid metabolism and leptin secretion in isolated porcine adipocytes. Dom Anim Endocrinol 2018; 63: 59-68
• 22 Sakurai T, Amemiya A, Ishii M. et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 1-696
• 23 Haynes AC, Jackson B, Chapman H. et al. A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul Pept 2000; 96: 45-51
• 24 Zink A, Bunney P, Holm A. et al. Neuromodulation of orexin neurons reduces diet-induced adiposity. Int J Obes 2018; 42: 737-745
• 25 Toshinai K, Yamaguchi H, Sun Y. et al. Des-acyl ghrelin induces food intake by a mechanism independent of the growth hormone secretagogue receptor. Endocrinology 2006; 147: 2306-2314
• 26 Burdakov D, Luckman SM, Verkhratsky A. Glucose-sensing neurons of the hypothalamus. Philosophical transactions of the Royal Society of London Series B, Biol Sci 2005; 360: 2227-2235
• 27 Gao S, Guo F, Sun X. et al. The inhibitory effects of Nesfatin-1 in ventromedial hypothalamus on gastric function and its regulation by nucleus accumbens. Front Physiol 2016; 7: 634
• 28 Barazzoni R, Bosutti A, Stebel M. et al. Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab 2005; 288: E228-E235
• 29 Dallak MA. Acylated ghrelin induces but deacylated ghrelin prevents hepatic steatosis and insulin resistance in lean rats: Effects on DAG/PKC/JNK pathway. Biomed Pharmacotherap 2018; 105: 299-311
• 30 Chunxue Z, Teegala S, Khan B. et al. Hypoglycemia: Role of Hypothalamic Glucose-Inhibited (GI) Neurons in Detection and Correction. Front Physiol 2018; 9: 192
• 31 Pozo M, Claret M. Hypothalamic control of systemic glucose homeostasis: the pancreas connection. Trends Endocrinol Metab 2018; 29: 581-594
• 32 Delhanty PJ, Sun Y, Visser JA. et al. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS One 2010; 5: e11749
• 33 Perna S, Spadaccini D, Gasparri C. et al. Association between des-acyl ghrelin at fasting and predictive index of muscle derangement, metabolic markers and eating disorders: A cross-sectional study in overweight and obese adults. Nutr Neurosci 2020; 15: 1-7
• 34 Gauna C, Meyler FM, Janssen JA. et al. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J Clin Endocrinol Metab 2004; 89: 5035-5042
• 35 Cassoni P, Ghe C, Marrocco T. et al. Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol 2004; 150: 173-184
• 36 Muccioli G, Pons N, Ghe C. et al. Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur J Pharmacol 2004; 498: 27-35
• 37 Ezquerro S, Mocha F, Fruhbeck G. et al. Ghrelin reduces TNF-alpha-Induced human hepatocyte apoptosis, autophagy, and pyroptosis: Role in Obesity-Associated NAFLD. J Clin Endocrinol Metab 2019; 104: 21-37
• 38 Chen CY, Inui A, Asakawa A. et al. Des-acyl ghrelin acts by CRF type 2 receptors to disrupt fasted stomach motility in conscious rats. Gastroenterology 2005; 129: 8-25
• 39 Stevanovic DM, Grefhorst A, Themmen AP. et al. Unacylated ghrelin suppresses ghrelin-induced neuronal activity in the hypothalamus and brainstem of male rats [corrected]. pLoS One 2014; 9: e98180
• 40 Liu L, Wang Q, Liu A. et al. Physological implications of orexins/hypocretins on energy metabolism and adipose tissue development. ACS Omega 2020; 5: 547-555
• 41 Monda V, Villano I, Messina A. et al. Aerobic exercise and orexin A: Role of sympathetic activity and redox system. J Biol Regulat Homestat Agents 2019; 33: 587-592
• 42 Polito R, Monda V, Nigro E. et al. The important role of adiponectin and orexin-A, Two key proteins improving healthy status: Focus on physical activity. Front Physiol 2020; 11: 356